Abstract:The CYP2A6 gene spans a region of approximately 6 kb pairs consisting of 9 exons and has been mapped to the long arm of chromosome 19 (between 19q12 and 19q13.2). The CYP2A6 protein has 494 amino acids and is an important hepatic Phase I enzyme that metabolizes approximately 3% of therapeutic drugs (n > 30; e.g. valproic acid, pilocarpine, tegafur, fadrozole, ifosfamide, cyclophosphamide, nicotine, tamoxifen, promazine, propofol, and cisapride), environmental toxicants (e.g. gasoline additives), and many procarcinogens such as nitrosamines and aflatoxin B(1). This enzyme also participates in the biotransformation of several endogenous compounds such as retinoid acids and steroids. Because CYP2A6 is responsible for 70-80% of the initial metabolism of nicotine, CYP2A6 has been proposed to be a novel target for smoking cessation. Site-directed mutagenesis and homology modeling studies have identified a number of amino acids (e.g. F300, A301, S208, S369, and L370) that play a role in substrate recognition and binding. CYP2A6 shows a crystal structure with a compact, hydrophobic active site with Asn297 serving as one hydrogen bond donor and orienting substrates for regio-selective oxidation. CYP2A6 contains the second smallest active site cavity among the human CYPs with known structures. The regulation mechanism of CYP2A6 expression is not fully understood, but available data suggest that several nuclear receptors including constitutive androstane receptor, pregnane X receptor and glucocorticoid receptor are involved in its regulation. Pilocarpine and tranylcypromine are commonly used as selective competitive inhibitors of CYP2A6. Selegiline, methoxsalen, (R)-(+) menthofuran and decursinol angelate are mechanism-based inhibitors of CYP2A6. Both in vitro and in vivo studies have demonstrated a wide (20- to >100-fold) interindividual variation in CYP2A6 expression and activity, which is due primarily to genetic polymorphisms in the CYP2A6 gene, but CYP2A6 activity is also modified by certain drugs and pathological and environmental factors. To date, more than 36 variant alleles (*1B through *37) of the CYP2A6 gene have been identified. There have been 278 SNPs found in the CYP2A6 upstream sequence, 8 introns and 9 exons in NCBI dbSNP. Polymorphism of CYP2A6 has been associated with smoking behavior, drug clearance and lung cancer risk. Further studies are warranted to explore the role of CYP2A6 in clinical practice, drug development and toxicology.

Polymorphisms of Human Cytochrome P450 2c9 and the Functional Relevance

Genetic Polymorphism of the Human Cytochrome P450 2C9 Gene and Its Clinical Significance.

Identification and Functional Assessment of EightCYP3A4Allelic Variants39–46Detected in the Chinese Han Population

Insights into the Substrate Specificity, Inhibitors, Regulation, and Polymorphisms and the Clinical Impact of Human Cytochrome P450 1A2

Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development

CYP2C9 Allelic Variants: Ethnic Distribution and Functional Significance.

Advances in Study of CYP2B6 Gene Polymorphisms and Its Functional Significances

New Insights into the Structural Features and Functional Relevance of Human Cytochrome P450 2C9. Part I.

Progress in research of cytochrome P450 3A4 gene polymorphism

Genetic Polymorphisms And In Silico Mutagenesis Analyses Of Cyp2c9, Cyp2d6, And Cypor Genes In The Pakistani Population

Genetic Polymorphism of CYP2C9 in Patients Receiving Warfarin Anticoagulant Therapy

FUNCTIONAL CHARACTERIZATION OF HUMAN CYP2C9 ALLELIC VARIANTS IN COS-7 CELLS

Recent Advance of Cytochrome P450 2C9

Impact of genetic and non-genetic factors on hepatic CYP2C9 expression and activity in Hungarian subjects

Identification and in vitro functional assessment of 10 CYP2C9 variants found in Chinese Han subjects

Structure, Function, Regulation and Polymorphism of Human Cytochrome P450 2A6

In Vitro Functional Characterization of 37 CYP2C9 Allelic Isoforms Found in Chinese Han Population.

Identification and Enzymatic Activity Evaluation of a Novel CYP2C9 Allelic Variant Discovered in a Patient

Genetic Variability in CYP3A5 and Its Possible Consequences

Identification And Functional Characterization Of New Potentially Defective Alleles Of Human Cyp2c19

Human CYP2C8: Structure, Substrate Specificity, Inhibitor Selectivity, Inducers and Polymorphisms